Related Experiment Videos

Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis

S J Khoury1, E J Orav, C R Guttmann

  • 1Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA 02115, USA. khoury@cnd.bwh.harvard.edu

Neurology
|September 17, 1999
PubMed
Abstract

Insights

Serum soluble intercellular adhesion molecule 1 (sICAM-1) and soluble tumor necrosis factor receptors (sTNF-Rs) levels correlate with multiple sclerosis (MS) disease activity. Changes in these markers can precede new MRI lesions, aiding in monitoring MS progression.

Area of Science:

  • Neuroimmunology
  • Biomarker Discovery
  • Multiple Sclerosis Research

Background:

  • Circulating adhesion molecules and soluble receptors may indicate cellular activation and inflammation.
  • These molecules can serve as potential biomarkers for inflammatory processes.

Purpose of the Study:

  • To investigate changes in serum soluble intercellular adhesion molecule 1 (sICAM-1) and soluble tumor necrosis factor receptors (sTNF-Rs) in MS patients.
  • To correlate these changes with clinical disease activity and brain MRI findings.

Main Methods:

  • A prospective longitudinal study over 1 year involving 40 MS patients.
  • Frequent brain MRI scans (22 per patient) and monthly neurological examinations.
  • Assessment of Kurtzke's Expanded Disability Status Scale (EDSS) and ambulation index (AI).

Main Results:

  • Relapsing-progressive MS patients showed highest sICAM-1; progressive MS patients showed highest sTNF-Rs.
  • sICAM-1 fluctuations correlated with relapses in relapsing and relapsing-progressive MS.
  • Increased sICAM-1 preceded new MRI lesions in relapsing-progressive MS; increased sTNF-R p55 preceded lesions in progressive MS.

Conclusions:

  • sICAM-1 and sTNF-R levels are linked to MS disease activity.
  • Progressive MS patients exhibit distinct immunologic profiles correlated with MRI changes.
  • These findings support the use of sICAM-1 and sTNF-Rs for monitoring MS progression and treatment response.

Related Concept Videos